ArticleCell biochemistry and biophysics2026
GPX7 Accelerates epithelial-mesenchymal Transition and Drives HCC Progression Via PI3K/AKT Signaling Pathway.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glutathione peroxidase 7 (GPX7) has been implicated in tumorigenesis and cancer progression across various malignancies. However, its functional role and clinical significance in hepatocellular carcinoma (HCC) remain poorly understood. The expression profile of GPX7 in HCC was analyzed using data from TCGA, GEO, and ICGC. Kaplan-Meier survival curves and receiver operating characteristic curve analysis were used to assess the prognostic and diagnostic value of GPX7. The drug sensitivity of GPX7 and functional enrichment analysis were investigated in the TCGA database. qRT-PCR, IHC, and WB validated the expression of GPX7 in HCC. CCK-8/EdU assayed to detect the effect of GPX7 on HCC proliferation and transwell assayed to detect the effect of GPX7 on HCC migration and invasion. Our analysis showed that GPX7 was upregulated in HCC normal counterparts. Elevated GPX7 was associated with decreased overall survival and increased diagnostic accuracy, as well as shown to correlate with chemoresistance in the TCGA database. Cell proliferation and metastasis were significantly inhibited by knockdown of GPX7 in HCC cell lines. Mechanistically, functional enrichment analysis and WB revealed that GPX7 overexpression could activate the PI3K/AKT pathway and epithelial-mesenchymal transition (EMT) to promote tumor progression. This study identifies GPX7 as a relevant oncogenic driver in HCC pathogenesis through PI3K-AKT/EMT axis activation. The strong diagnostic properties and chemoresistance modulation make GPX7 a promising therapeutic biomarker for the treatment of HCC.
Indexed as
Identifiers
41071487What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.